Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Ad26.ZEBOV and MVA-BN-Filo as Prophylactic Ebola Vaccines
2019-000691-42Phase 3
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2019
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zabdeno and Mvabea in Ebola virus disease (EVD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Solicited local and systemic adverse events (reactogenicity).
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on 2019-000691-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000691-42.